These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26359680)

  • 1. Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase Inhibitor.
    Liu C; Lin J; Hynes J; Wu H; Wrobleski ST; Lin S; Dhar TG; Vrudhula VM; Sun JH; Chao S; Zhao R; Wang B; Chen BC; Everlof G; Gesenberg C; Zhang H; Marathe PH; McIntyre KW; Taylor TL; Gillooly K; Shuster DJ; McKinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
    J Med Chem; 2015 Oct; 58(19):7775-84. PubMed ID: 26359680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.
    Liu C; Lin J; Wrobleski ST; Lin S; Hynes J; Wu H; Dyckman AJ; Li T; Wityak J; Gillooly KM; Pitt S; Shen DR; Zhang RF; McIntyre KW; Salter-Cid L; Shuster DJ; Zhang H; Marathe PH; Doweyko AM; Sack JS; Kiefer SE; Kish KF; Newitt JA; McKinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
    J Med Chem; 2010 Sep; 53(18):6629-39. PubMed ID: 20804198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38α inhibitor.
    Liu C; Lin J; Everlof G; Gesenberg C; Zhang H; Marathe PH; Malley M; Galella MA; McKinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2013 May; 23(10):3028-33. PubMed ID: 23578688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).
    Cai ZW; Zhang Y; Borzilleri RM; Qian L; Barbosa S; Wei D; Zheng X; Wu L; Fan J; Shi Z; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Kamath A; Marathe P; D'Arienzo C; Derbin G; Barrish JC; Robl JA; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
    J Med Chem; 2008 Mar; 51(6):1976-80. PubMed ID: 18288793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of carbon-11-labeled 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine derivatives as new potential PET tracers for imaging of p38α mitogen-activated protein kinase.
    Wang M; Gao M; Zheng QH
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3700-5. PubMed ID: 25065491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
    Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
    J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors.
    Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly KM; Shuster DJ; Doweyko AM; Sack JS; Kish K; Kiefer SE; Newitt JA; Zhang H; Marathe PH; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4633-7. PubMed ID: 21705217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, bioconversion, pharmacokinetic and pharmacodynamic evaluation of N-isopropyl-oxy-carbonyloxymethyl prodrugs of CZh-226, a potent and selective PAK4 inhibitor.
    Guo J; Wang T; Wu T; Zhang K; Yin W; Zhu M; Pang Y; Hao C; He Z; Cheng M; Liu Y; Zheng J; Gu J; Zhao D
    Eur J Med Chem; 2020 Jan; 186():111878. PubMed ID: 31757524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor.
    Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Schieven GL; Gillooly KM; Shuster DJ; Taylor TL; Yang X; McIntyre KW; McKinnon M; Zhang H; Marathe PH; Doweyko AM; Kish K; Kiefer SE; Sack JS; Newitt JA; Barrish JC; Dodd J; Leftheris K
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1762-7. PubMed ID: 18313298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.
    Aston NM; Bamborough P; Buckton JB; Edwards CD; Holmes DS; Jones KL; Patel VK; Smee PA; Somers DO; Vitulli G; Walker AL
    J Med Chem; 2009 Oct; 52(20):6257-69. PubMed ID: 19772287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
    Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
    J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Characterization of (
    Bristow LJ; Gulia J; Weed MR; Srikumar BN; Li YW; Graef JD; Naidu PS; Sanmathi C; Aher J; Bastia T; Paschapur M; Kalidindi N; Kumar KV; Molski T; Pieschl R; Fernandes A; Brown JM; Sivarao DV; Newberry K; Bookbinder M; Polino J; Keavy D; Newton A; Shields E; Simmermacher J; Kempson J; Li J; Zhang H; Mathur A; Kallem RR; Sinha M; Ramarao M; Vikramadithyan RK; Thangathirupathy S; Warrier J; Islam I; Bronson JJ; Olson RE; Macor JE; Albright CF; King D; Thompson LA; Marcin LR; Sinz M
    J Pharmacol Exp Ther; 2017 Dec; 363(3):377-393. PubMed ID: 28954811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
    Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
    J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An oral sphingosine 1-phosphate receptor 1 (S1P(1)) antagonist prodrug with efficacy in vivo: discovery, synthesis, and evaluation.
    Angst D; Janser P; Quancard J; Buehlmayer P; Berst F; Oberer L; Beerli C; Streiff M; Pally C; Hersperger R; Bruns C; Bassilana F; Bollbuck B
    J Med Chem; 2012 Nov; 55(22):9722-34. PubMed ID: 23067318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 2. Synthesis and characterization of a novel imide-type prodrug for improving oral absorption.
    Okaniwa M; Imada T; Ohashi T; Miyazaki T; Arita T; Yabuki M; Sumita A; Tsutsumi S; Higashikawa K; Takagi T; Kawamoto T; Inui Y; Yoshida S; Ishikawa T
    Bioorg Med Chem; 2012 Aug; 20(15):4680-92. PubMed ID: 22763369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.
    Brown DS; Cumming JG; Bethel P; Finlayson J; Gerhardt S; Nash I; Pauptit RA; Pike KG; Reid A; Snelson W; Swallow S; Thompson C
    Bioorg Med Chem Lett; 2012 Jun; 22(12):3879-83. PubMed ID: 22608965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043).
    Kadow JF; Ueda Y; Meanwell NA; Connolly TP; Wang T; Chen CP; Yeung KS; Zhu J; Bender JA; Yang Z; Parker D; Lin PF; Colonno RJ; Mathew M; Morgan D; Zheng M; Chien C; Grasela D
    J Med Chem; 2012 Mar; 55(5):2048-56. PubMed ID: 22356441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological activity of pyridopyridazin-6-one p38α MAP kinase inhibitors. Part 2.
    Tynebor RM; Chen MH; Natarajan SR; O'Neill EA; Thompson JE; Fitzgerald CE; O'Keefe SJ; Doherty JB
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5979-83. PubMed ID: 22901390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.